A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD ...

Thanks to Joanna from Poland, I have no measurable leukemia. Getting college-age kids to join the bone-marrow donor registry ...

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

GVHD is a common and often fatal complication that can follow a bone marrow transplant, which occurs when the donated cells mount an immune response against the transplant recipient’s tissues ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

A new study finds that eliminating radiation from conditioning regimens in patients with dyskeratosis congenita undergoing ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

In August, Incyte and its partner Syndax announced the U.S. Food and Drug Administration (FDA) approval of Niktimvo, an ...

Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. Find out ...

Graft versus host disease (GvHD) market, valued at $3.0 billion in 2021, is on a significant growth trajectory, projected to reach $10.4 billion by 2031. David Correa Allied Market Research email us ...